New Hope in Alzheimer’s Research
Alzheimer’s disease poses significant challenges to brain health, often leading to irreversible damage. However, a recent study shines a light on the possibility that some of this neurological harm might be reversible.
Researchers in the United States discovered that a compound known as P7C3-A20 improved cognitive functions in mice with Alzheimer’s-like conditions. It halted brain cell damage, reduced inflammation, and even restored the protective blood-brain barrier.
“We were very excited and encouraged by our results,” notes Andrew Pieper, a neuroscientist and psychiatrist from Case Western Reserve University.
P7C3-A20 was chosen because it’s a neuroprotective substance that helps restore NAD+ levels. NAD+, which stands for nicotinamide adenine dinucleotide, is vital for cellular fuel and protein synthesis.
Earlier animal studies have indicated that using compounds like P7C3-A20 to restore NAD+ levels can alleviate symptoms of Alzheimer’s. Interestingly, some researchers have also shown its effective use in repairing mouse brains after head injuries.
In this follow-up experiment, normal NAD+ levels were achieved in mice with advanced symptoms after six months of daily injections. Related markers for inflammation and DNA damage suggested that cells could function normally once again.
The team utilized two mouse models of Alzheimer’s, each reflecting different aspects of the disease—specifically, amyloid-beta plaques and tau protein tangles. These protein clumps are thought to contribute to neuron death and disruption of brain function, though the exact dynamics remain somewhat murky. While P7C3-A20 improved brain function, it didn’t eliminate these clumps, hinting that neurons might manage the aggregated proteins if their energy levels are balanced.
“Restoring the brain’s energy balance achieved both pathological and functional recovery in both lines of mice with advanced Alzheimer’s,” Pieper observed.
He further adds, “Observing this effect across two distinct animal models, driven by different genetic factors, strengthens the notion that recovery from advanced disease may be feasible in humans with Alzheimer’s when the brain’s NAD+ levels are normalized.”
Of course, there’s a substantial journey ahead before confirming if treatments like this can effectively reverse Alzheimer’s damage in humans. This will necessitate more animal experimentation and well-structured clinical trials. Nevertheless, the findings underscore the potential importance of NAD+ in future therapies.
Yet, it’s crucial to approach these treatments with caution. An excessive amount of NAD+ has previously been linked to cancer, and considering the complexity of Alzheimer’s, a multifaceted approach may be necessary.
“The key takeaway is a message of hope – the impacts of Alzheimer’s may not be permanently fixed,” Pieper emphasizes. “The damaged brain can, under certain conditions, repair itself and regain function.”
The findings have been published in Cell Reports Medicine.
